I see what you're saying, but the ultimate goal here would be to get the FDA to come to some agreement where the approval process is expedited (seeing as how there's already an industry developing), and sales would be allowed to continue provided certain benchmarks are met in that process. This isn't my idea, many others have posted those sentiments. I have no idea if it's a realistic proposal. Assuming it is, the industry needs to give the FDA reason to think that it will make those benchmarks, and this could be a good step in the right direction. Not to mention that some of the requisite tests would already be done for both approval processes.
Sure, but there is a clear distinction between the "industry" and "company". As such, industry and FDA should not be used in the same sentence, it holds no merit. Same goes for "approval" and "manufacturing".
Look at it this way:
Step1. Who are you and what you are doing
Step2. Provide supporting data
Step3. Validate via Pier-Review
Step4. Conduct the trial
After those steps are complete, you get into manufacturing, QC standards, labeling, taxes, audits and such. While your ideas are absolutely spot-on, they address manufacturing and completely bypass 1-4.
EDIT TO CLARIFY
This only applies if FDA maintains it's current position, without allowing sales. In case that changes, you will certainly have to take the steps you proposed while simultaneously conducting 1-4. Perhaps that's exactly the strategy of JC.
Last edited: